EPS Bio Technology Corp.

As of June 30, 2026, EPS Bio Technology Corp. carries a market capitalization of 316.54M, placing it among publicly traded companies globally. Its enterprise value stands at 322.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, EPS Bio Technology Corp. has 23.80M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.76, and the price-to-book ratio stands at 1.18.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.77 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 322.88M versus a market cap of 316.54M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, EPS Bio Technology Corp. maintains a current ratio of 2.30, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 51.58, indicating elevated leverage, while an interest coverage ratio of -2.19 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, EPS Bio Technology Corp. posted a negative return on equity (ROE) of -10.21, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.55, reflecting losses generated across the asset base. The company generates approximately 3.80M in revenue per employee across its workforce of 110.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.00 indicates how many times EPS Bio Technology Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, EPS Bio Technology Corp. recorded an income tax benefit of -3.23M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -32.48M and -29.25M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, EPS Bio Technology Corp.'s stock has declined approximately 20.56% over the past 52 weeks. The 50-day moving average sits at 14.13, while the 200-day moving average is 15.49.

Over the twelve months ended June 30, 2026, EPS Bio Technology Corp. generated 418.46M in revenue and converted that into -29.25M in net income, yielding earnings per share of -1.22. EBITDA reached -4.87M, while operating income came in at -18.20M.

As of June 30, 2026, EPS Bio Technology Corp. holds 131.56M in cash and equivalents against 137.90M in total debt, resulting in a net debt position of -82.48M. Total book value stands at 267.35M, with working capital of 184.69M providing operational flexibility.

EPS Bio Technology Corp. produced 6.10M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -18.31M in capital expenditures, free cash flow totaled -12.21M - equivalent to -0.51 per share.

Over the twelve months ended June 30, 2026, EPS Bio Technology Corp. posted a gross margin of 17.44, reflecting its pricing power and cost economics. The operating margin of -4.35 and net profit margin of -6.99 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, EPS Bio Technology Corp. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -3.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.71, meaning EPS Bio Technology Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

EPS Bio Technology Corp.'s most recent stock split took place on October 8, 2014 with a 25:26 split ratio.

As of June 30, 2026, EPS Bio Technology Corp. has an Altman Z-Score of 1.91, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.